Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer

被引:28
作者
Bechmann, Troels [1 ,2 ]
Andersen, Rikke Fredslund [3 ]
Pallisgaard, Niels [3 ]
Madsen, Jonna Skov [1 ,3 ]
Maae, Else [2 ]
Jakobsen, Erik Hugger [2 ]
Jylling, Anne Marie Bak [4 ]
Steffensen, Karina Dahl [5 ]
Jakobsen, Anders [1 ,2 ]
机构
[1] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark
[2] Vejle Hosp, Dept Oncol, Vejle, Denmark
[3] Vejle Hosp, Dept Biochem, Vejle, Denmark
[4] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark
[5] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
关键词
Breast cancer; Cell-free DNA; HER2; amplification; Neoadjuvant chemotherapy; CIRCULATING TUMOR DNA; REAL-TIME PCR; ADJUVANT CHEMOTHERAPY; QUANTITATIVE PCR; SERUM; TRASTUZUMAB; SURVIVAL; PLUS; RNA; QUANTIFICATION;
D O I
10.1007/s00432-013-1413-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Measurement of human epidermal growth factor receptor 2 (HER2) gene amplification in cell-free DNA (cfDNA) is an evolving technique in breast cancer, enabling liquid biopsies and treatment monitoring. The present study investigated the dynamics of plasma HER2 gene copy number and amplification in cfDNA during neoadjuvant chemotherapy. The study included 50 patients from a prospective cohort analyzed during neoadjuvant chemotherapy. Fifty healthy women with no history of cancer served as control group and 15 patients with metastatic breast cancer were used to validate the assay. Total cfDNA and HER2 gene amplification were measured by quantitative real-time polymerase chain reaction. Plasma HER2 gene copy number (p = 0.794), HER2 gene amplification (p = 0.127) and total cfDNA (p = 0.440) did not differ significantly from the levels in the control group. Eighteen patients (36 %) obtained pathological complete response (pCR). HER2 gene copy number before the operation was significantly higher than the baseline level (p < 0.0001), but there was no difference between patients with and without pCR (p = 0.569). Likewise, there was no difference in plasma HER2 gene amplification between tissue HER2-positive and -negative patients (p = 0.754). The results indicate that neither total cfDNA nor HER2 gene copy number is elevated in primary breast cancer patients compared to healthy controls. The level of both parameters increased during neoadjuvant chemotherapy, but without any relation to treatment effect. There was no indication of plasma HER2 gene amplification in the HER2-positive patients in the neoadjuvant setting.
引用
收藏
页码:995 / 1003
页数:9
相关论文
共 39 条
[1]   Plasma is Superior to Serum for CfDNA Mutation Detection and Monitoring [J].
Andersen, R. F. ;
Spindler, K. G. ;
Jakobsen, A. ;
Pallisgaard, N. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 :148-149
[2]   Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients [J].
Anker, P ;
Mulcahy, H ;
Chen, XQ ;
Stroun, M .
CANCER AND METASTASIS REVIEWS, 1999, 18 (01) :65-73
[3]   Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome [J].
Bergqvist, J. ;
Ohd, J. F. ;
Smeds, J. ;
Klaar, S. ;
Isola, J. ;
Nordgren, H. ;
Elmberger, G. P. ;
Hellborg, H. ;
Bjohle, J. ;
Borg, A.-L. ;
Skoog, L. ;
Bergh, J. .
ANNALS OF ONCOLOGY, 2007, 18 (05) :845-850
[4]   Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer [J].
Catarino, Raquel ;
Ferreira, Maria M. ;
Rodrigues, Helena ;
Coelho, Ana ;
Nogal, Ana ;
Sousa, Abreu ;
Medeiros, Rui .
DNA AND CELL BIOLOGY, 2008, 27 (08) :415-421
[5]   An Alternative and Reliable Real-time Quantitative PCR Method to Determine HER2/neu Amplification in Breast Cancer [J].
Egervari, Kristof ;
Toth, Judit ;
Nemes, Zoltan ;
Szollosi, Zoltan .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (03) :247-254
[6]   Methylated DNA and Total DNA in Serum Detected by One-Step Methylation-Specific PCR Is Predictive of Poor Prognosis for Breast Cancer Patients [J].
Fujita, Noriko ;
Nakayama, Takahiro ;
Yamamoto, Noriaki ;
Kim, Seung Jin ;
Shimazu, Kenzo ;
Shimomura, Atsushi ;
Maruyama, Naomi ;
Morimoto, Koji ;
Tamaki, Yasuhiro ;
Noguchi, Shinzaburo .
ONCOLOGY, 2012, 83 (05) :273-282
[7]   Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR [J].
Gal, S ;
Fidler, C ;
Lo, YMD ;
Taylor, M ;
Han, C ;
Moore, J ;
Harris, AL ;
Wainscoat, JS .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1211-1215
[8]   Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders [J].
Galeazzi, M ;
Morozzi, G ;
Piccini, M ;
Chen, J ;
Bellisai, F ;
Fineschi, S ;
Marcolongo, R .
AUTOIMMUNITY REVIEWS, 2003, 2 (01) :50-55
[9]   Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer [J].
Gong, Bo ;
Xue, Jianxiang ;
Yu, Jing ;
Li, Haichuan ;
Hu, Heyu ;
Yen, Hsuehheng ;
Hu, Jinyin ;
Dong, Qianggang ;
Chen, Fuhua .
ONCOLOGY LETTERS, 2012, 3 (04) :897-900
[10]   DNA integrity in plasma and serum of patients with malignant and benign diseases [J].
Holdenrieder, Stefan ;
Burges, Alexander ;
Reich, Oliver ;
Spelsberg, Fritz W. ;
Stieber, Petra .
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, 2008, 1137 :162-170